Abbvie Inc
ABBV
Market Cap$283.25B
Close$
Earnings Call Q4 2023
February 2, 2024 - AI Summary
AbbVie reported strong fourth quarter and full-year 2023 results, with revenues exceeding expectations and growth in the base business excluding Humira.
The company's growth platform, which includes Skyrizi, Rinvoq, Vraylar, Ubrelvy, and Qulipta, delivered double-digit sales growth in 2023 and is expected to continue driving growth in 2024.
AbbVie reaffirmed its long-term sales outlook, including a return to robust revenue growth in 2025 and a high single-digit CAGR through the end of the decade.
Exclusive for Stockcircle Pro members
Sign up
$175.52
9.2% upside
Current Fair Value
9.2% upsideUndervalued by 9.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $283.25 Billion |
|---|---|
| Enterprise Value | $339.18 Billion |
| Dividend Yield | $5.9761 (3.73%) |
| Earnings per Share | $3.36 |
| Beta | 0.31 |
| Outstanding Shares | 1,765,867,781 |
| Avg 30 Day Volume | 5,460,908 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 47.6 |
|---|---|
| PEG | 9.59 |
| Price to Sales | 5.36 |
| Price to Book Ratio | 40.19 |
| Enterprise Value to Revenue | 6.23 |
| Enterprise Value to EBIT | 25.29 |
| Enterprise Value to Net Income | 56 |
| Total Debt to Enterprise | 0.22 |
| Debt to Equity | 9.24 |
Revenue Sources
No data
ESG Score
No data
About Abbvie Inc
CEO: Richard Gonzalez